What Do Analysts Think About GeneDx Holdings Corp. (WGS)?
TheFly reported that on December 22, 2025, GeneDx Holdings Corp. (NASDAQ:WGS) lifted its price objective at Canaccord from $160 to $170. Canaccord continued to rate the shares as a Buy.
Genedx Holdings Corp. (WGS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Impax Asset Management Ian Simm | 60,000 | $7,803,600 | +20% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $60.52 | 24,644 | $1,491,454.88 | 3,058,629 | 2025-05-14 | Filing | |
| $59.81 | 25,356 | $1,516,542.36 | 3,033,985 | 2025-05-14 | Filing | |
| $57.53 | 9,867 | $567,648.51 | 3,008,629 | 2025-05-08 | Filing | |
| $56.96 | 10,897 | $620,693.12 | 2,998,762 | 2025-05-08 | Filing | |
| $55.69 | 79,236 | $4,412,652.84 | 2,987,865 | 2025-05-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $140.45 | 127 | $17,837.15 | 8,731 | 2025-12-16 | Filing | |
| $150.75 | 26 | $3,919.50 | 8,858 | 2025-12-16 | Filing | |
| $149.20 | 97 | $14,472.21 | 8,884 | 2025-12-16 | Filing | |
| $148.55 | 331 | $49,169.92 | 8,981 | 2025-12-16 | Filing | |
| $146.93 | 699 | $102,702.81 | 9,312 | 2025-12-16 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 381,725 | $49,647,154 | 0.03% | |
| 2. | 205,895 | $26,778,704 | 0.04% | |
| 3. | 198,926 | $25,872,315 | 0.01% | |
| 4. | 87,164 | $11,336,550 | 4.28% | |
| 5. | 59,650 | $7,758,079 | 3.59% |
News See All
Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat
On October 29, 2025, Guggenheim lifted GeneDx (NASDAQ:WGS) to a $170 price target (Buy) after the company's blow-out Q3 announcement a day earlier.
10 Best Digital Health Stocks to Buy Now
Digital health’s 2025 shape is pretty clear: money is flowing again, AI is getting absorbed into real workflows, and policy is quietly forcing the pipes to talk to each other.
GeneDx Holdings Corp. (NASDAQ:WGS) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the GeneDx Third Quarter 2025 Earnings Conference Call. [Operator Instructions].
GeneDx Holdings Corp. (NASDAQ:WGS) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the GeneDx Second Quarter 2025 Earnings Conference Call.
Guggenheim Raises GeneDx (WGS) Price Target, Maintaining a Buy Rating
Guggenheim analyst Subbu Nambi has raised the price target for GeneDx Holdings Corp (NASDAQ:WGS) from $88.00 to $115.00, reinforcing a bullish stance on the company’s long-term trajectory.
Top 10 Healthcare AI Stocks to Buy According to Hedge Funds
“Healthcare is the most underappreciated AI beneficiary,” said Ark Invest CEO Cathie Wood in a recent statement that’s reverberating across Wall Street.
GeneDx Holdings Corp. (NASDAQ:WGS) Q1 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the GeneDx First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
10 Best Multibagger Stocks to Buy According to Billionaires
US Trade tariffs have triggered heightened volatility and amplified the downdraft in the equity markets.
GeneDx Holdings Corp. (WGS) Rose on Robust Customer Demand
Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Hedge Fund Resource Center Billionaire Hedge Funds
